Group 1 Automotive (GPI) Given Daily News Impact Rating of 0.11

News articles about Group 1 Automotive (NYSE:GPI) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Group 1 Automotive earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.126593523058 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Group 1 Automotive traded up $1.65, reaching $74.92, during mid-day trading on Friday, according to MarketBeat. 250,160 shares of the company were exchanged, compared to its average volume of 165,222. Group 1 Automotive has a 52 week low of $51.62 and a 52 week high of $84.47. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.06 and a quick ratio of 0.27. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of 9.69, a price-to-earnings-growth ratio of 1.22 and a beta of 1.76.

Get Group 1 Automotive alerts:

Group 1 Automotive (NYSE:GPI) last issued its earnings results on Thursday, April 26th. The company reported $1.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.54 by $0.16. The business had revenue of $2.86 billion during the quarter, compared to the consensus estimate of $2.66 billion. Group 1 Automotive had a return on equity of 15.47% and a net margin of 1.86%. The firm’s revenue for the quarter was up 13.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.53 earnings per share. sell-side analysts anticipate that Group 1 Automotive will post 8.61 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, June 15th. Shareholders of record on Friday, June 1st were issued a $0.26 dividend. The ex-dividend date was Thursday, May 31st. This represents a $1.04 dividend on an annualized basis and a yield of 1.39%. Group 1 Automotive’s payout ratio is currently 13.45%.

Group 1 Automotive announced that its Board of Directors has authorized a share buyback program on Wednesday, May 16th that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the company to repurchase up to 6.7% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its stock is undervalued.

A number of brokerages have recently issued reports on GPI. Morgan Stanley raised their price objective on Group 1 Automotive from $53.00 to $62.00 and gave the stock an “underweight” rating in a research report on Wednesday, March 14th. Zacks Investment Research upgraded Group 1 Automotive from a “hold” rating to a “buy” rating and set a $83.00 price objective for the company in a research report on Tuesday, June 12th. Buckingham Research downgraded Group 1 Automotive from a “buy” rating to a “neutral” rating in a research report on Tuesday, March 20th. ValuEngine downgraded Group 1 Automotive from a “buy” rating to a “hold” rating in a research report on Tuesday, March 20th. Finally, Stephens restated a “hold” rating and set a $86.00 price objective on shares of Group 1 Automotive in a research report on Wednesday, March 21st. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. Group 1 Automotive has an average rating of “Hold” and a consensus target price of $81.75.

About Group 1 Automotive

Group 1 Automotive, Inc, through its subsidiaries, operates in the automotive retail industry. It sells new and used cars, light trucks, and vehicle parts; arranges vehicle financing; sells service and insurance contracts; and provides automotive maintenance and repair services. The company has operations primarily in the metropolitan areas of Alabama, California, Florida, Georgia, Kansas, Louisiana, Maryland, Massachusetts, Mississippi, New Hampshire, New Jersey, New Mexico, Oklahoma, South Carolina, and Texas in the United States; 28 towns in the United Kingdom; and in the metropolitan markets of Sao Paulo, Parana, Mato Grosso do Sul, and Santa Catarina, Brazil.

Opiant Pharmaceuticals (OPNT) Receives Daily Coverage Optimism Score of 0.14

Media coverage about Opiant Pharmaceuticals (NASDAQ:OPNT) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Opiant Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the technology company an impact score of 45.1070496888511 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Opiant Pharmaceuticals stock traded up $0.22 during mid-day trading on Friday, reaching $14.86. The company’s stock had a trading volume of 23,332 shares, compared to its average volume of 14,618. The company has a market cap of $38.29 million, a P/E ratio of 5.05 and a beta of -0.84. Opiant Pharmaceuticals has a 12 month low of $5.06 and a 12 month high of $51.90.

Get Opiant Pharmaceuticals alerts:

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its earnings results on Tuesday, May 8th. The technology company reported ($3.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($3.39). The business had revenue of $1.70 million during the quarter, compared to the consensus estimate of $2.00 million. Opiant Pharmaceuticals had a negative net margin of 379.64% and a negative return on equity of 574.62%. analysts predict that Opiant Pharmaceuticals will post -5.86 earnings per share for the current fiscal year.

OPNT has been the subject of a number of analyst reports. ValuEngine raised shares of Opiant Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. Cantor Fitzgerald initiated coverage on shares of Opiant Pharmaceuticals in a research report on Monday, June 11th. They issued a “buy” rating and a $32.00 target price for the company.

In other news, Director Ann L. Macdougall purchased 5,000 shares of the business’s stock in a transaction on Monday, June 4th. The stock was purchased at an average price of $16.51 per share, for a total transaction of $82,550.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David D. O’toole purchased 3,000 shares of the business’s stock in a transaction on Friday, May 11th. The stock was purchased at an average price of $18.85 per share, with a total value of $56,550.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 10,000 shares of company stock valued at $173,000. Corporate insiders own 63.82% of the company’s stock.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Goldman Sachs Expects Marcus to Get ��Very Big, Very Profitable��

Goldman Sachs Group Inc.’s push into consumer finance has even bigger aims than investors might imagine.

Personal loans are just the start, with possible expansion opportunities for its Marcus brand in mortgages, credit cards, auto loans and insurance, Goldman Sachs President David Solomon said in a presentation Thursday.

“We don’t have to be one of the big leading consumer banks -- we can have a narrow slice of share and have a very big, very profitable, very differentiated business over a period of time,” Solomon said. “We’re building it as a platform for Goldman Sachs over the next 50 years.”

Since the consumer bank started in 2016, it’s attracted 1.5 million customers, made over $3 billion of loans and gathered $22 billion of digital deposits, Solomon said. Goldman Sachs is planning to expand Marcus into Europe with operations in Germany and the U.K. It also acquired personal-finance app Clarity Money to increase the customer base.

Solomon likened the consumer bank to the start of Goldman Sachs’s investment-management business 30 years ago. As onlookers focus on the firm’s installment lending, Solomon pointed instead to the “broad vision to build this platform” and its ability to link the bank’s other services like wealth management.

He said the bank could be expanding consumer loans faster, but it’s being “cautious” because of concern that the credit cycle may turn.

LISTEN TO ARTICLE 1:23 Share Share on Facebook Post to Twitter Send as an Email Print